1995•InfectionRequires access

Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice

Noel Karalus, J. E. Garrett, S. D. R. Lang, R. A. Leng, G. N. Kostalas, Ray Cursons, B. C. Cooper, C. J. Ryan

Open publisher page 12 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Roxithromycin, Clavulanic acid, Medicine, Tolerability, Amoxicillin, Regimen, Antibiotics, Respiratory tract infections

Back to paper search Browse research topics Original source

Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice — Research Paper | ScholarLens